AD

Adagene Inc.

ADAGHealthcareNASDAQ

Biotechnology · Last scanned Jun 27, 2026

PriceMA150MA200
Loading chart…
End-of-day data · ScananceOpen live chart on TradingView ↗
Indicator snapshot
MA150+37.83%
$3.04

Price above medium-term moving average.

MA200+52.36%
$2.75

Above long-term trend line.

RSI-14overbought
73.0

Above 70 — may be overbought.

MACDpositive
+0.0809

Histogram positive — upward momentum.

Financials · Annual
Revenue
$7.7M
+7332.8% YoY
Net Income
-$17.6M
+47.3% YoY
EBITDA
-$16.9M
+46.7% YoY
Free Cash Flow
-$10.3M

Scan Results

Daily timeframe

1 of 4 indicators bearish as of Jun 26

DateIndicatorDetails
Jun 27 RSI OverboughtRSI 73.0 — above 70, stock may be overbought
Jun 18 MACD Positive CrossoverHistogram +0.0053 — positive momentum
About Adagene Inc.

Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. The company carries a $276.8M market cap, placing it firmly in the micro-cap category. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer.

Key stats
Market Cap$276.8M
Fwd P/E-8.06
EPS$-0.38
Beta0.59
52W Change+118.2%
ROE-34.4%
Analysis

The balance sheet looks solid with $75.8M in cash comfortably exceeding the $6.3M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$10.3M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -34.4%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has been uneven over recent years, ranging from $9.3M to $7.7M.

ADAG's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. With cash comfortably exceeding debt, ADAG has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing ADAG's risk profile alongside its fundamentals and technical indicators provides a more complete picture.

Links
Not financial advice. Scanance is an educational tool. Past performance does not guarantee future results.PrivacyTerms